Provided by Tiger Trade Technology Pte. Ltd.

Lixte Biotechnology Holdings Inc.

3.97
-0.0753-1.86%
Volume:41.68K
Turnover:167.68K
Market Cap:22.67M
PE:-3.28
High:4.15
Open:4.15
Low:3.95
Close:4.05
52wk High:6.26
52wk Low:0.6400
Shares:5.70M
Float Shares:5.41M
Volume Ratio:0.53
T/O Rate:0.77%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2110
EPS(LYR):-1.5943
ROE:-130.06%
ROA:-68.32%
PB:9.61
PE(LYR):-2.49

Loading ...

Lixte Biotechnology Holdings Inc. held annual shareholder meeting

Reuters
·
Dec 12

Lixte Biotechnology Holdings Inc. Outlines Strategy to Expand Oncology Platform with Complementary Modalities, Advancing PP2A Inhibitor Development and Integrating Radiotherapy Technologies

Reuters
·
Dec 08

Lixte Biotechnology Holdings Inc. Outlines Strategy to Advance LB-100 Combination Therapy, Strengthen Financial Foundation, and Support Multi-Year Clinical Development

Reuters
·
Dec 03

Lixte Biotechnology Acquires Liora Technologies for Growth

TIPRANKS
·
Nov 26

BUZZ-U.S. STOCKS ON THE MOVE-Applied Materials, CDW,  Kohl's

Reuters
·
Nov 25

BUZZ-Lixte rises after buying UK firm to enter proton therapy cancer care

Reuters
·
Nov 25

Lixte Biotechnology acquires Liora’s proton therapy platform

TIPRANKS
·
Nov 25

Lixte Biotechnology Acquires Liora Technologies’ Proprietary Proton Therapy Platform for Cancer Treatment

THOMSON REUTERS
·
Nov 25

Lixte Biotechnology Holdings Inc. Announces Date for Upcoming Annual Stockholders Meeting

Reuters
·
Oct 17

Lixte Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate Lb-100, Strategic Oncology Business Development and Acquisition Plans

THOMSON REUTERS
·
Oct 16

Lixte Biotechnology Holdings Inc. Announces Leadership Reshuffle with Geordan Pursglove as CEO and Bas van der Baan as Chief Scientific Officer

Reuters
·
Sep 16

Lixte Biotechnology Invests $2.6M in Cryptocurrencies

TIPRANKS
·
Sep 12

Lixte Biotechnology purchases 10.5 Bitcoin, 300 Ethereum for $2.6M

TIPRANKS
·
Sep 11

Lixte Biotechnology Holdings Inc - Purchases 10.5 Bitcoin and 300 Ethereum for $2.6 Mln

THOMSON REUTERS
·
Sep 11

Lixte Biotechnology Holdings Inc. Files Initial Beneficial Ownership Statement for Director Guy Primus

Reuters
·
Sep 11

Lixte Biotechnology Holdings Inc. Announces Breakthrough Clinical Trial for LB-100, the World's Only Clinical-Stage PP2A Inhibitor, Targeting Cancer Treatment Synergies

Reuters
·
Sep 05

Lixte Biotechnology Holdings Inc. Files Initial Statement of Beneficial Ownership for Director Felix Lourdes

Reuters
·
Sep 05

BRIEF-Lixte Biotechnology Holdings Inc - Peter Stazzone Has Been Named Chief Financial Officer

Reuters
·
Sep 03

Lixte Biotechnology Holdings Appoints Two New Board Members and New Chief Financial Officer

THOMSON REUTERS
·
Sep 03

24/7 Market News: LIXTE Showcases LB-100 at First Global Conference on Oncogenic Signaling Activation as Cancer Therapy

GlobeNewswire
·
Aug 27